AZN logo
AZN
AstraZeneca

Expanding Emerging Markets And Precision Medicine Will Transform Healthcare

AN
AnalystHighTarget
AnalystHighTarget
Not Invested
Consensus Narrative from 19 Analysts
Published
27 Jul 25
Updated
27 Jul 25
AnalystHighTarget's Fair Value
UK£171.34
34.5% undervalued intrinsic discount
27 Jul
UK£112.20
Loading
1Y
-9.6%
7D
0.6%

Author's Valuation

UK£171.3

34.5% undervalued intrinsic discount

AnalystHighTarget Fair Value